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Abstract Autopsy studies have shown that about 55% of
patients with frontotemporal lobar degeneration (FTLD)
and 25% of patients with Alzheimer’s disease (AD) har-
bour TDP-43 immunoreactive pathological changes in their
brains. Using ELISA, we investigated whether we could
detect the presence, or increased amounts, of TDP-43 in
plasma of patients with FTLD and AD compared to normal
control subjects. We detected elevated levels of TDP-43
protein in plasma of 46% patients with FTLD with clinical
frontotemporal dementia (FTD) and 22% patients with AD,
compared to 8% of control subjects. The proportions of
patients with FTD and AD showing raised plasma TDP-43
levels correspond closely to those proportions known from
autopsy studies to contain TDP-43 pathological changes in
their brains. Raised TDP-43 plasma levels may thereby
index TDP-43 pathology within the brain. Plasma TDP-43
levels may be a biomarker that can provide a laboratory test
capable of identifying the presence of TDP-43 brain pathol-
ogy in neurodegenerative disease during life. It may help to
distinguish those cases of FTLD with ubiquitin/TDP-43
pathology in their brains from those with tauopathy. As a
predictive test, plasma TDP-43 level may have great practi-
cal value in directing therapeutic strategies aimed at pre-
venting or removing tau or TDP-43 pathological changes
from the brain in FTLD and AD.
Keywords Frontotemporal lobar degeneration · 
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Introduction
Recent research in neurodegenerative disease has high-
lighted the importance of a new molecular entity, the TAR
DNA binding protein, TDP-43 (see [6] for review). Prior to
the discovery in 2006 that TDP-43 was the target protein in
the ubiquitinated cytoplasmic inclusions in neurones in cer-
tain histological forms of frontotemporal lobar degenera-
tion (FTLD) known as FTLD-ubiquitinated (FTLD-U), and
in motor neurone disease (MND) [2, 24], little was known
of the function of this 414 amino acid nuclear protein
beyond it serving a role in nuclear transcription in relation-
ship to alternative splicing or exon skipping [5, 30] The
involvement of TDP-43 in the ubiquitinated lesions of
FTLD-U and MND has now been amply conWrmed [6, 7, 9,
17, 29]. While ubiquitinated TDP-43 lesions are character-
istically seen in those patients with inherited forms of
FTLD associated with mutations in progranulin gene
(PGRN) [3,  4,  8,  9,  16,  26,  28], in other patients with
FTLD, such as those with mutations in tau gene (MAPT), or
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in those with a Pick body-type histology, where the under-
lying histology is based on the accumulation of aggregated
tau proteins, no such TDP-43 pathological changes are seen
[9]. Moreover, other studies have shown that TDP-43 path-
ological changes can also occur in about 20% of patients
with Alzheimer’s disease (AD) [1] and are widely present
in patients with Lewy body diseases [21] or with parkinson-
ism-dementia complex of Guam [12].
Present data therefore suggest a widespread involvement
of TDP-43 in neurodegenerative disease beyond FTLD-U
and MND. In clinical terms, about 70% of patients with
FTLD show behavioural and personality changes which are
collectively described as frontotemporal dementia (FTD)
[23]. Prospective and retrospective pathological studies
have indicated that about half of all cases with FTD have a
tau-positive, TDP-43-negative pathology, and half have
ubiquitin-positive, TDP-43-positive pathology [10, 14, 15,
20, 27]. Nevertheless, in patients with FTLD, it is presently
not possible to predict, in life, what the underlying histolog-
ical changes might be solely on the basis of clinical pheno-
type, and it is only in that minority of patients where
mutations in MAPT or PGRN are present that a tau or ubiq-
uitin/TDP-43 based histology, respectively, can be conW-
dently inferred.
The diVerential diagnosis of dementia syndromes is clin-
ical and radiological, and there are no litmus tests based on
measures in blood or plasma to specify diagnosis. A bio-
chemical marker that could distinguish between AD and
FTLD, or between the histological subtypes of FTLD,
would be not only of great diagnostic value, but would be
highly pertinent to the future development of drugs aimed
at preventing or removing the intraneuronal accumulation
of tau or TDP-43 proteins in these degenerative disorders.
Given the pathological observations that a proportion of
patients with AD [1] or FTLD [9, 14, 15, 19, 27] harbour
TDP-43 pathological changes within their brains, it can be
hypothesised that similar proportions of patients might
show altered blood or plasma levels of TDP-43, and that
this could be a useful biomarker of the presence of TDP-43
brain pathology.
In this present study we have investigated whether TDP-
43 can be detected in plasma in patients with FTD and AD,
and in normal control subjects, by developing an ELISA-
based assay. We show that not only can TDP-43 be
detected in plasma, but more importantly, that the level of
this is elevated in a proportion of each group of patients
similar to that seen in patients with known TDP-43 brain
pathology. Measurement of plasma TDP-43 may therefore
have utility in evidencing the presence of brain TDP-43
based pathologies in neurodegenerative disease, and per-
haps more importantly be capable of discriminating during
life those patients with FTLD associated with ubiquitin/
TDP-43 pathological changes in their brains from those
with tauopathy, when a deWning mutation in MAPT or
PGRN is absent.
Materials and methods
Blood samples
Blood samples were obtained with Ethical permissions from
137 patients, 35 with FTD and 102 with AD, and 85 non-
demented control subjects (Table 1). All patients with FTD
and AD had been assessed (by DN, JSS) within out-patient
clinics at the Cerebral Function Unit, Greater Manchester
Neurosciences Centre. All patients had undergone historical
interview in the presence of a family caregiver and compre-
hensive cognitive assessment to obtain information about
the nature and progression of cognitive and functional
decline. Patients with AD and FTD fulWlled the National
Institute of Neurological and Communicative Disorders and
Stroke—Alzheimer’s Disease and Related Disorders Asso-
ciation (NINCDS-ADRDA) criteria for probable AD [18]
and International criteria for FTD [22], respectively. Control
subjects were either spouses of patients attending CFU
clinic (n = 13), or a sample of healthy volunteers (n = 72)
drawn randomly from a cohort of 767 mentally normal peo-
ple aged >50 years, resident within the same Greater Man-
chester region from which the AD and FTD patients were
recruited [25]. The latter comprised a longitudinal ageing
study group who had been screened psychologically for
absence of cognitive impairment consistent with dementia.
All blood samples had been collected with the approval of
the local ethics research committee.
Plasma was separated from whole blood samples (5 ml
blood with EDTA acting as anti-coagulant) by routine
methods, and stored in deep freeze (¡80°C) until assay.
Table 1 Details of groups of patients with AD and FTD, and control
subjects, at the time when blood samples were taken
Control AD FTD
Patients (n) 85 102 35
Age range (years) 42–83 43–88 42–78
Mean age (years) § SD 71.3 § 8.3 64.2 § 9.3 62.4 § 8.2
Mean age of onset 
(years) § SD
n/a 61.5 § 9.4 69.7 § 8.4
Mean disease duration 
(years) § SD
n/a 2.9 § 1.8 2.7 § 2.1
Gender: Male:Female% (n) 43.5:56.5 
(37:48)
51.9:48.1 
(53:49)
48.6:51.4 
(17:18)
Mean absorbance value 0.02 0.13 0.26
Median absorbance value ¡0.04 0.02 0.11
Percentage of samples over 
the 0.11 cut-oV point (%)
8.8 23 46Acta Neuropathol (2008) 116:141–146 143
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Immunoassay protocol
An antibody-sandwich ELISA was developed to measure
the TDP-43 concentration in plasma samples. The ELISA
plates (96-well PVC assay plates, Iwaki, Japan) were
coated by overnight incubation at 4°C with 0.2 g/ml anti-
TDP monoclonal antibody (H00023435-M01, clone 2E2-
D3, Abnova Corporation, Taiwan), 100 l/well, diluted in
200 mM NaHCO3 buVer, pH 9.6, containing 0.02% (w/v)
sodium azide. The plates were washed 3 times with PBST
(PBS (0.01 M phosphate buVer, 0.0027 M potassium chlo-
ride and 0.137 M sodium chloride, pH 7.4) containing
0.05% Tween 20), and incubated with 200 l/well of block-
ing buVer (PBS containing 2.5% gelatin and 0.05% Tween
20) for 2 h at 37°C. The plates were again washed 3 times
with PBST, and 100 l of the plasma samples to be tested,
diluted 1:1 with PBS, were added to each of three wells.
After washing 3 times with PBST, 100 l of the detection
antibody, TDP rabbit polyclonal antibody (BC001487, Pro-
teinTech Group, Chicago) diluted to 0.2 g/ml in blocking
buVer, was added per well and the plates were incubated at
37°C for 2 h. After another wash (as before), the plates
were incubated with 100 l/well of goat anti-rabbit second-
ary antibody coupled to horseradish peroxidase (HRP)
(Dako Ltd., Ely, U.K.), diluted 1:10,000 in blocking buVer,
at 37°C for 1 h. The plates were then washed again with
PBST, before adding 100 l/well Sure Blue TMB Micro-
well Peroxidase Substrate (KPL Inc, Maryland, USA) and
leaving the colour to develop for 30 min at room tempera-
ture. Finally, 100 l/well of stop solution (0.3 M H2SO4)
was added and absorbance values were read at 450 nm in a
Victor2 multi-function microtitre plate reader. Net absor-
bance was calculated by deducting the mean value obtained
for a triplicate of “blank” wells containing PBS only.
The antibody-sandwich ELISA using polyclonal TDP-
43 antibody (BC001487) as capture antibody was also suc-
cessful and gave similar signals. However, the monoclonal
antibody (2E2-D3) was chosen as the preferred capture
antibody as background signals were smaller.
Recombinant TDP-43 protein (MW 54.3 KDa)
(AAH01487, 1 -261, Abnova Corporation, Taiwan, with 26
KDa GST tag) was used in the standard curve.
Immunoprecipitation of TDP-43 from plasma
Dynabeads covalently coupled with recombinant protein A,
were derivatised with rabbit polyclonal anti-TDP-43 anti-
body (BC001487, ProteinTech Group, Chicago) as recom-
mended by the manufacturer (Dynal Biotech LTD.,Wirral,
UK). 300 l plasma was added to the beads and incubated
overnight at 4°C. The plasma samples were chosen accord-
ing to the ELISA results, with one sample giving a high sig-
nal and the other a low signal. The beads were then washed
three times with 0.1 M phosphate buVer, pH 8.2. Any cap-
tured TDP-43 was eluted from the beads by boiling for 10
min in NuPAGE LDS sample buVer (Invitrogen Ltd., UK)
and examined by gel electrophoresis and immunoblotting.
Gel electrophoresis and immunoblotting
The protein eluted from the magnetic dynabeads (see
above) was separated on NUPAGE Bis-Tris 4-12%, 1 mm
gels (Invitrogen). The separated proteins were transferred
to nitrocellulose membranes (0.45 m, Invitrogen) at 30 V,
125 mA for 1 h. Membranes were blocked with 5% Marvel
dried skimmed milk, dissolved in PBST for 1 h. The mem-
branes were probed overnight at 4°C with either anti-TDP-
43 antibody, rabbit polyclonal (BC001487, ProteinTech
Group, Chicago) 1:1,000 in PBST, or anti-TDP-43 mouse
monoclonal antibody (H00023435-M01, clone 2E2-D3,
Abnova Corporation, Taiwan) 1:1,000 in PBST, as indi-
cated. The membranes were washed three times in PBST,
followed by incubation with HRP-conjugated goat anti-rab-
bit or goat anti-mouse (Dako LTD., Ely, U.K.), 1:10,000
in PBST, as appropriate, for 1 h. The protein bands were
visualised using ECL reagents (Pierce, Rockford, IL) as
described by the manufacturer.
Statistical analyses
All data were analysed using SPSS v 14.0. Because OD
values for FTD and AD patients, as well as control subjects
were not normally distributed according to Kolmogorov-
Smirnov test, non-parametric Kruskal-Wallis test was used
throughout to compare groups, with post hoc Mann-Whit-
ney test being employed when the results of Kruskal-Wallis
test yielded signiWcant group diVerences.
Results
A standard curve for the ELISA is shown in Fig. 1. The
ELISA data from the plasma samples indicate that in control
subjects, in most instances, TDP-43 was barely detectable
(mean § SD, OD = 0.02 § 0.32), with just 8 individuals
(8.8%) having absorbance (optical density or OD) values
exceeding 0.11 (Fig. 2). This value corresponds to the 99%
upper conWdence level and was subsequently chosen to rep-
resent the ‘cut oV’ point of ‘normal’ TDP-43 values. In AD,
TDP-43 was again barely detectable in 79 patients (78%)
(Fig. 2), though OD exceeded 0.11 in 23 patients (22%). In
FTD, 16/35 patients (46%) patients had OD value exceeding
0.11 (Fig. 2). The proportion of patients with OD greater
than 0.11 diVered signiWcantly across the groups (2 = 19.8;
P < 0.001) with the proportion of patients with OD values
greater than 0.11 being signiWcantly higher in both FTD144 Acta Neuropathol (2008) 116:141–146
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(2 = 20.4; P < 0.001) and AD (2 = 5.8; P = 0.016) com-
pared to controls, and in FTD compared to AD (2 = 6.9;
P = 0.009). Consequently, the mean OD values for control
subjects (0.02 § 0.32) and patients with FTD (0.26 § 0.52)
and AD (0.13 § 0.33) were signiWcantly diVerent by Kruskal-
Wallis test (2 = 53.2; P < 0.001), with post hoc Mann-
Whitney test showing mean values for both FTD and AD
groups to be signiWcantly diVerent from controls (P < 0.001),
with mean OD in FTD group also being signiWcantly greater
(P = 0.037) than that in AD.
When protein from plasma samples with high levels of
TDP-43 (based on ELISA results) was immunocaptured
with magnetic Dynabeads coupled to the anti-TDP-43 rab-
bit polyclonal antibody, and then examined by gel electro-
phoresis and western blotting employing the anti-TDP-43
monoclonal antibody for detection, only a single band
migrating at »43 kDa was seen (Fig. 3, lane 2). No speciWc
bands were detected in similarly treated low-reading
plasma samples.
There were no signiWcant correlations between plasma
TDP-43 level and age at onset of illness, or duration of ill-
ness up to time of sampling, for AD and FTD groups, either
when the whole AD or FTD group, or just those individuals
with high TDP-43 levels, were considered.
Discussion
In the present study we have shown for the Wrst time that
the TAR DNA-binding protein, TDP-43, can be detected
within plasma of normal control people, as well as individ-
uals with neurodegenerative diseases such as AD and FTD.
The ELISA data indicate that TDP-43 is present at
extremely low concentrations, or is absent, in the vast
majority of normal people, and in AD or FTD there are sub-
stantial numbers of patients in whom TDP-43 is likewise
barely present. However, group comparisons by ELISA
reveal a highly signiWcant increase (approximately 13-fold)
in mean TDP-43 absorbance levels in FTD compared to
controls, whereas in AD the mean TDP-43 absorbance level
was about 7-fold increased. The validity of the ELISA
method is supported by the immunoblotting results. In
accord with the ELISA data, an immunoreactive band
migrating at 43 kDa, which corresponds precisely to the
molecular weight of full-length TDP-43 [2,  24] was
detected only in the high-reading plasma sample and not in
the low-reading sample. This result not only conWrms the
speciWcity of the antibody pair employed for the sandwich
Fig. 1 Standard curve for the TDP-43 ELISA (data show mean § SD)
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ELISA, but also shows that the readout from the ELISA
accurately reXects the levels of TDP-43 present in plasma.
From histological studies, it is known that about 50% of
patients with FTD have ubiquitin/TDP-43-based histology
[6,  7,  10,  14,  15,  20,  27] and consequently it might be
expected that a similar proportion of patients with this kind
of pathology would be included within the present unse-
lected FTD study group. In the present FTD cohort, there
was a highly signiWcant mean increase in plasma TDP-43
absorbance levels, with about 46% patients showing ‘high’
TDP-43 levels (ie above OD of 0.11 corresponding to 99%
upper control limit). On the basis of autopsy studies [6, 7,
9] such a proportion of patients would have been antici-
pated if the presence of TDP-43 in plasma is indeed index-
ing the presence of TDP-43 pathology in brain. Likewise,
in AD it is known that about 20–25% patients have TDP-
43-based pathology [1] and again it might be anticipated
that within the present group of unselected AD cases, a
similar proportion of cases with TDP-43 pathology would
exist. In the present AD group 22% patients showed ‘high’
TDP-43 values, while in most patients no increase was
seen. Therefore the proportion of patients showing high
plasma TDP-43 levels in both FTD and AD closely match,
at least in numerical terms, those proportions that would be
predicted to occur from histological studies.
The few elderly control subjects with high TDP-43 lev-
els (8%) may be patients with incipient neurodegenerative
disease, most likely AD, since it has long been known that a
very high proportion of mentally normal elderly subjects
show at autopsy some degree of Alzheimer-type pathologi-
cal changes in their brains (ie senile plaques and neuro-
Wbrillary tangles), and this may, as in AD itself, include
some individuals with additional TDP-43 pathology.
Indeed, the proportion of control subjects showing raised
plasma TDP-43 levels recorded here is similar to the preva-
lence rate of elderly individuals with mild cognitive impair-
ment. [11,  13,  19], supporting the view that such
individuals might represent cases of early or incipient AD
with additional TDP-43 pathological changes.
Although the numerical similarities between the propor-
tions of patients with FTD and AD showing ‘high’ TDP-43
plasma levels and those displaying TDP-43 pathological
changes at autopsy argue that measurement of plasma TDP-
43 level can index the presence of TDP-43 pathology
within the brain of patients with FTD or AD, we accept that
these numerical associations may simply be fortuitous, or
may reXect, for example, a compromised blood-brain bar-
rier in FTD and AD, and recognise that the data we have
presented here, although intriguing, is still very much pre-
liminary. Present data, and the arguments we have pre-
sented based on this data, would be greatly strengthened if
autopsy follow-up of patients with AD or FTD with high
plasma TDP-43 values were available. However, because
the patients investigated here were still in the early or mid-
dle stages of their illness when blood samples were taken,
this will not be possible for many years to come. An alter-
native approach would be to compare plasma TDP-43 lev-
els in FTD patients bearing MAPT or PGRN mutations,
since it is known from histological studies that patients with
MAPT mutations and tauopathy do not show TDP-43 path-
ological changes in their brains [9], whereas those with
PGRN mutation always display TDP-43 pathological
changes [3, 4, 8, 9, 16, 26, 28]. Hence, by the present argu-
ment, patients with MAPT mutations should show low
(normal) plasma TDP-43 levels and those with PGRN
mutations should show high(er) plasma TDP-43 levels.
Unfortunately, within the present cohort of FTD patients
there was only one bearer of PGRN mutation (in whom the
plasma TDP-43 level was raised), and no bearers of MAPT
mutation, so at present we are not realistically able to
address this issue. We are presently aiming to collect fur-
ther plasma samples from the surviving MAPT and PGRN
mutation bearers within our FTD cohort. Until then, present
data suggest, but do not deWnitively show, that measure-
ment of plasma TDP-43 level might discriminate in life,
those patients with FTD or AD with TDP-43 pathology
from those without TDP-43 pathology (ie those with tau-
based histological changes), even if it does not diVerentiate
between patients with AD or FTD per se.
Because all patients investigated were (when sampled)
in early to middle stages of disease it has not been possible
so far to follow or deduce how changes in plasma TDP-43
levels might change with disease progression or disease
severity. Further studies based on repeat sampling from
patients with elevated plasma TDP-43 levels will address
this matter.
Although we do not know the biological or functional
signiWcance of (the additional) TDP-43 pathology in
patients with AD, as with FTD, there may be heuristic
(future) management or therapeutic values in being able to
predict the presence of TDP-43 changes in such patients.
Given the possibility of tau- or TDP-43-based therapies
becoming available for patients with AD or FTD, knowing
who in AD or FTD is potentially able to beneWt from tau
and/or TDP-43 based therapy, according to predictive
knowledge of underlying histology, would be of consider-
able practical value.
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